(Q38868960)

7 September 2017

1 reference

title

Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality? (English)

1 reference

7 September 2017

0 references

Anja Saso

1

1 reference

7 September 2017

Beate Kampmann

series ordinal

2

1 reference

7 September 2017

publication date

14 June 2016

1 reference

Lancet Infectious Diseases

7 September 2017

published in

1 reference

7 September 2017

volume

16

1 reference

7 September 2017

issue

8

1 reference

7 September 2017

page(s)

e153-63

1 reference

Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Respiratory syncytial virus-associated mortality in hospitalized infants and young children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

The path to an RSV vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

1 reference

7 January 2021

Burden of respiratory syncytial virus infection in young children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

The burden of respiratory syncytial virus infection in young children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Epidemiology of respiratory syncytial virus infection in preterm infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Respiratory syncytial virus and recurrent wheeze in healthy preterm infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Respiratory Syncytial Virus Infection in High-risk Infants - an Update on Palivizumab Prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Current concepts and progress in RSV vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Immune responses and disease enhancement during respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Immunity to RSV in Early-Life.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

The role of Th17 and Treg responses in the pathogenesis of RSV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Animal models of human respiratory syncytial virus disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

The natural history of respiratory syncytial virus in a birth cohort: the influence of age and previous infection on reinfection and disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Immunity to and frequency of reinfection with respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Vaccination against RSV: is maternal vaccination a good alternative to other approaches?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

CD8+ T cell responses in bronchoalveolar lavage fluid and peripheral blood mononuclear cells of infants with severe primary respiratory syncytial virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Cell-mediated Immunity to Respiratory Syncytial Virus Induced by Inactivated Vaccine or by Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Respiratory syncytial viral infection in children with compromised immune function

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Human respiratory syncytial virus nonstructural protein NS2 antagonizes the activation of beta interferon transcription by interacting with RIG-I

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Protective and dysregulated T cell immunity in RSV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

The role of T cells in the enhancement of respiratory syncytial virus infection severity during adult reinfection of neonatally sensitized mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Immunopathogenesis of vaccine-enhanced RSV disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Biological challenges and technological opportunities for respiratory syncytial virus vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Strategic priorities for respiratory syncytial virus (RSV) vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Advances in and the potential of vaccines for respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Respiratory syncytial virus: current progress in vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Prospects for defined epitope vaccines for respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Respiratory syncytial virus vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Virus-like particles: passport to immune recognition

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Adenoviruses as vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Genetic stability of RSV-F expression and the restricted growth phenotype of a live attenuated PIV3 vectored RSV vaccine candidate (MEDI-534) following restrictive growth in human lung cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phas

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Progress and challenges in RSV prophylaxis and vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Maternal immunization as a strategy to decrease susceptibility to infection in newborn infants.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Maternal immunization. Clinical experiences, challenges, and opportunities in vaccine acceptance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Maternal immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Influenza and tetanus, diphtheria, and acellular pertussis vaccinations during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Persistent recurring wheezing in the fifth year of life after laboratory-confirmed, medically attended respiratory syncytial virus infection in infancy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

The significance of transplacental antibody against respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

IgG placental transfer in healthy and pathological pregnancies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Serum antibody decay in adults following natural respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Role of serum neutralizing antibody in reinfection of respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Key terms for the assessment of the safety of vaccines in pregnancy: Results of a global consultative process to initiate harmonization of adverse event definitions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

The changing landscape of respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Immunogenicity and Clinical Efficacy of Influenza Vaccination in Pregnancy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

A prospective cohort study comparing the reactogenicity of trivalent influenza vaccine in pregnant and non-pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Effectiveness of maternal influenza immunization in mothers and infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Safety of influenza vaccines in pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Neonatal outcomes after antenatal influenza immunization during the 2009 H1N1 influenza pandemic: impact on preterm birth, birth weight, and small for gestational age birth

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Neonatal outcomes after influenza immunization during pregnancy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Influenza vaccination of pregnant women and protection of their infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Understanding pregnant women's attitudes and behavior toward influenza and pertussis vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Increased awareness and health care provider endorsement is required to encourage pregnant women to be vaccinated

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

[Implementation of the influenza vaccination recommendation in nursing homes in Germany : results of a survey as part of the national influenza immunization campaign].

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

What determines uptake of pertussis vaccine in pregnancy? A cross sectional survey in an ethnically diverse population of pregnant women in London

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Seasonal variations in maternal serum and mammary immunity to RS virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Influence of maternal antibodies on neonatal immunization against respiratory viruses.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Effects of maternal and infant co-infections, and of maternal immunisation, on the infant response to BCG and tetanus immunisation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Insights into the regulatory mechanism controlling the inhibition of vaccine-induced seroconversion by maternal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Evaluating vaccination strategies for reducing infant respiratory syncytial virus infection in low-income settings

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Social, economic, and health impact of the respiratory syncytial virus: a systematic search

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

A global perspective of maternal influenza immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

The influence of placental malaria infection and maternal hypergammaglobulinemia on transplacental transfer of antibodies and IgG subclasses in a rural West African population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Placental antibody transfer: influence of maternal HIV infection and placental malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

The transplacental transfer of IgG subclasses: influence of prematurity and low birthweight in the Gambian population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Epidemiology of respiratory syncytial virus-associated acute lower respiratory tract infection hospitalizations among HIV-infected and HIV-uninfected South African children, 2010-2011.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Factors affecting the infant antibody response to measles immunisation in Entebbe-Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Impact of anthelminthic treatment in pregnancy and childhood on immunisations, infections and eczema in childhood: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Respiratory syncytial virus circulation in seven countries with Global Disease Detection Regional Centers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Considerations of strategies to provide influenza vaccine year round

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Interventions to reduce neonatal mortality from neonatal tetanus in low and middle income countries--a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Translating vaccine policy into action: a report from the Bill & Melinda Gates Foundation Consultation on the prevention of maternal and early infant influenza in resource-limited settings

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Path to impact: A report from the Bill and Melinda Gates Foundation convening on maternal immunization in resource-limited settings; Berlin - January 29-30, 2015.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

Influenza vaccine acceptance among pregnant women in urban slum areas, Karachi, Pakistan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2816%2900119-5

7 January 2021

10.1016/S1473-3099(16)00119-5

Identifiers

DOI

1 reference

7 September 2017

1 reference